Novo Nordisk's Ozempic, Wegovy sales jump 40% in India after steep price cuts

Novo Nordisk moved 32,000 units of Ozempic and Wegovy in India in April 2026, a 40% surge after slashing prices 36-48%. Starting doses now retail at Rs 5,660 as the Danish drugmaker defends share against newly launched generic semaglutide rivals in the booming obesity drug market.

— FiledSun, 21 Jun, 2026, 00:54 IST·First seen Sun, 21 Jun, 2026, 00:53 IST·Source Moneycontrol · Results

What happened

Novo Nordisk's Ozempic and Wegovy sales jumped 40% in India in April 2026 to 32,000 units after 36-48% price cuts brought starting doses to Rs 5,660, defending

Key facts

  • 40% sales surge
  • 32,000 units in April
  • 36% price cut Ozempic
  • 48% price cut Wegovy
  • 5,660 rupees starting dose
  • $60

Why this matters

India's accelerating GLP-1 adoption at sub-$70 starting doses opens partnership and supply-chain plays with local generics, distributors, and obesity-care platforms now that Novo has reset the price anchor.

Also reported by